Clinical trial
HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
NCT06236269
Study timeline
Study start (actual)2024-03-15Date precision: day
Registry last updated2024-07-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancer Stage IVunresolved
Interventions
Sacituzumab GovitecanDRUG · verified · RxNorm: sacituzumab govitecan
Sponsors & collaborators
SOLTI Breast Cancer Research Grouplead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06236269 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.